We’re excited to announce a new funding partnership with US-based charity, Cure CMD, to fund research into LMNA congenital muscular dystrophy (LMNA-CMD); the LMNA-CMD Partnership.
LMNA-CMD is a very rare condition that starts at an early age, commonly in the first few months of a child’s life, and causes muscle weakness and often problems with heart and respiratory function.
Research is needed to better understand the underlying cellular mechanisms of the condition, to generate better animal models and to develop potential treatments. Biomarkers are also needed, for monitoring progression and measuring the effectiveness of potential treatments being tested in clinical trials.
By working in collaboration with Cure CMD, we are able to boost investment into high quality research for this serious and rare condition.
The LMNA-CMD Partnership has been announced to international researchers who have been invited to apply. These applications will be submitted to Muscular Dystrophy UK where they will be considered, alongside other applications to the charity, in 2018.
The grant applications will be assessed using our rigorous selection process, which is based on the Association of Medical Research Charities’ (AMRC) criteria for peer-reviewed research funding, and the opinions of Muscular Dystrophy UK’s Medical Research Committee. This ensures that only projects with a sufficiently high standard of scientific and/or clinical quality are funded.
Chief Executive of Muscular Dystrophy UK, Robert Meadowcroft, commented:
We are delighted to be working in collaboration with Cure CMD to boost research into LMNA congenital muscular dystrophy. The LMNA-CMD Partnership will ensure a greater investment into research that will increase our understanding of LMNA congenital muscular dystrophy and aid the potential development of effective treatments; this means a great deal to the families whose children are affected by this very rare condition.
Research Director at Cure CMD, Dr Gustavo Dziewczapolski, commented:
We believe collaboration is key to meaningful research that will move the needle towards treatments and a cure. Our recent five-conference series focused on collaboration among scientists, and we are honoured and excited to continue in this spirit with Muscular Dystrophy UK.